title: Conversion from calcineurin inhibitors to everolimus with low-dose cyclosporine in renal transplant recipients with squamous cell carcinoma of the skin.
abstract: Squamous cell carcinoma of the skin (SCC) is the most frequent cancer in renal transplant recipients. Conversion to mammalian target of rapamycin inhibitors after diagnosis of SCC may reduce the incidence of recurrence of skin cancer. This retrospective study evaluated the outcome of renal transplant recipients followed by the Renal Unit with posttransplant diagnosis of SCC treated with conversion from calcineurin inhibitors (CNIs) to Everolimus (EVR) associated with low-dose cyclosporine. Eleven patients developed SCC at a median time from renal transplantation of 107 months (range 36-264). Five patients with creatinine clearance (CCl) below 40 mL/min before conversion developed end stage renal disease (two cases) or further deterioration of renal function (two cases); only one patient in this group maintained a stable renal function. The remaining six patients with a CC1 greater than 40 mL/min and proteinuria below 0.8 g/24 hours maintained a stable renal function after conversion to EVR at a median follow-up of 22 months (range 15-75). Conversion from CNIs to EVR has been proven safe, effective, and associated with low recurrence of SCC in patients with a CCl >40 mL/min. In the case of preexisting deterioration of renal function or significant proteinuria, conversion to EVR should be carefully evaluated.
authors.affiliation: Renal Unit, AOU Careggi, Florence, Italy. leonardocaroti@yahoo.it
authors.forename: L
authors.initials: L
authors.lastname: Caroti
authors.forename: M
authors.initials: M
authors.lastname: Zanazzi
authors.forename: N
authors.initials: N
authors.lastname: Paudice
authors.forename: A
authors.initials: A
authors.lastname: Tsalouchos
authors.forename: P
authors.initials: P
authors.lastname: Carta
authors.forename: A
authors.initials: A
authors.lastname: Larti
authors.forename: N
authors.initials: N
authors.lastname: Pimpinelli
authors.forename: L
authors.initials: L
authors.lastname: Moscarelli
authors.forename: M
authors.initials: M
authors.lastname: Salvadori
authors.forename: E
authors.initials: E
authors.lastname: Bertoni
mesh_terms: D065095:Calcineurin Inhibitors; D002294:Carcinoma, Squamous Cell / Q000473:pathology*; D016572:Cyclosporine / Q000008:administration & dosage / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D000068338:Everolimus; D006801:Humans; D016030:Kidney Transplantation; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000494:pharmacology; D012878:Skin Neoplasms / Q000473:pathology*
chemical_list: D065095:Calcineurin Inhibitors; D016572:Cyclosporine; D000068338:Everolimus; D020123:Sirolimus